Advanced search
1 file | 716.73 KB

Fish hydrolysates : a regulatory perspective of bioactive peptides

Bert Gevaert (UGent) , Lieselotte Veryser (UGent) , Frederick Verbeke (UGent) , Evelien Wynendaele (UGent) and Bart De Spiegeleer (UGent)
(2016) PROTEIN AND PEPTIDE LETTERS. 23(12). p.1052-1060
Author
Organization
Abstract
For the first time introduced on the Japanese market, bioactive fish hydrolysates are now available all over the world as food supplements, functional food ingredients or nutricosmeceuticals. They are generally produced from low value fish waste, an almost inexhaustible source of raw material, and are sold as high value products, making them economically interesting from a manufacturer's view point. Most of these products have health or structure/function claims on their packages with different actions like antihypertensive, blood-glucose lowering, anxiolytic, and skin anti-aging activities. Although the different regional legislations all aim to assure consumer safety and prevent misleading of the consumer, the number of legally approved fish hydrolysate containing products drastically differs among different regions. This is because products that have been positively evaluated based on safety and efficacy in one region were found to have not enough evidence for efficacy in another region. These findings call for further international harmonization of the regulation and classification of these products. Moreover, interaction studies of these bioactive products with the normal diet or medicines are generally not performed, keeping the consumer uninformed of the possible risks of combining these products with medicinal products or other food ingredients.
Keywords
Bioactive marine peptides, fish hydrolysates, legal classification, regulatory affairs, HEALTH CLAIMS, HYPERTENSIVE SUBJECTS, DIETARY-SUPPLEMENTS, BLOOD-PRESSURE, PROTEIN, FOOD, RAT, KATSUOBUSHI, CAPTOPRIL, SYSTEM

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 716.73 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Gevaert, Bert, Lieselotte Veryser, Frederick Verbeke, Evelien Wynendaele, and Bart De Spiegeleer. 2016. “Fish Hydrolysates : a Regulatory Perspective of Bioactive Peptides.” Protein and Peptide Letters 23 (12): 1052–1060.
APA
Gevaert, B., Veryser, L., Verbeke, F., Wynendaele, E., & De Spiegeleer, B. (2016). Fish hydrolysates : a regulatory perspective of bioactive peptides. PROTEIN AND PEPTIDE LETTERS, 23(12), 1052–1060.
Vancouver
1.
Gevaert B, Veryser L, Verbeke F, Wynendaele E, De Spiegeleer B. Fish hydrolysates : a regulatory perspective of bioactive peptides. PROTEIN AND PEPTIDE LETTERS. 2016;23(12):1052–60.
MLA
Gevaert, Bert, Lieselotte Veryser, Frederick Verbeke, et al. “Fish Hydrolysates : a Regulatory Perspective of Bioactive Peptides.” PROTEIN AND PEPTIDE LETTERS 23.12 (2016): 1052–1060. Print.
@article{8507591,
  abstract     = {For the first time introduced on the Japanese market, bioactive fish hydrolysates are now available all over the world as food supplements, functional food ingredients or nutricosmeceuticals. They are generally produced from low value fish waste, an almost inexhaustible source of raw material, and are sold as high value products, making them economically interesting from a manufacturer's view point. Most of these products have health or structure/function claims on their packages with different actions like antihypertensive, blood-glucose lowering, anxiolytic, and skin anti-aging activities. Although the different regional legislations all aim to assure consumer safety and prevent misleading of the consumer, the number of legally approved fish hydrolysate containing products drastically differs among different regions. This is because products that have been positively evaluated based on safety and efficacy in one region were found to have not enough evidence for efficacy in another region. These findings call for further international harmonization of the regulation and classification of these products. Moreover, interaction studies of these bioactive products with the normal diet or medicines are generally not performed, keeping the consumer uninformed of the possible risks of combining these products with medicinal products or other food ingredients.},
  author       = {Gevaert, Bert and Veryser, Lieselotte and Verbeke, Frederick and Wynendaele, Evelien and De Spiegeleer, Bart},
  issn         = {0929-8665},
  journal      = {PROTEIN AND PEPTIDE LETTERS},
  keyword      = {Bioactive marine peptides,fish hydrolysates,legal classification,regulatory affairs,HEALTH CLAIMS,HYPERTENSIVE SUBJECTS,DIETARY-SUPPLEMENTS,BLOOD-PRESSURE,PROTEIN,FOOD,RAT,KATSUOBUSHI,CAPTOPRIL,SYSTEM},
  language     = {eng},
  number       = {12},
  pages        = {1052--1060},
  title        = {Fish hydrolysates : a regulatory perspective of bioactive peptides},
  url          = {http://dx.doi.org/10.2174/0929866523666161102122637},
  volume       = {23},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: